Leads Biolabs Advances Opamtistomig Phase II Trial in First-Line Liver Cancer
NANJING, China, August 6, 2026 Leads Biolabs announced that its Phase II clinical study evaluating Opamtistomig (LBL-024) in combination...
X-body Platform
Advertisement
Advertisement
